ES2190075T3 - Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. - Google Patents

Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.

Info

Publication number
ES2190075T3
ES2190075T3 ES98918648T ES98918648T ES2190075T3 ES 2190075 T3 ES2190075 T3 ES 2190075T3 ES 98918648 T ES98918648 T ES 98918648T ES 98918648 T ES98918648 T ES 98918648T ES 2190075 T3 ES2190075 T3 ES 2190075T3
Authority
ES
Spain
Prior art keywords
sae
therapeutic agent
pharmaceutical formulations
sulfoalquil
cyclodextrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98918648T
Other languages
English (en)
Inventor
Valentino K Stella
James Macginity
Roger A Rajewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cydex Pharmaceuticals Inc
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Application granted granted Critical
Publication of ES2190075T3 publication Critical patent/ES2190075T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas a base de sulfoalquil éter-ciclodextrina (SAE-CD), las cuales contienen derivados de SAE-CD y un agente terapéutico, cuya mayor parte no está unida por complejo a la SAE-CD. Las formulaciones de la presente invención frecen la ventaja de una preparación más fácil que las otras formulaciones a base de SAE-CD del estado anterior de la técnica a la par que tienen una eficacia similar, incluso mejorada. El derivado de SAE-CD puede utilizarse para modificar la biodisponibilidad y/o el nivel de bioabsorción de los agentes terapéuticos.
ES98918648T 1997-05-05 1998-04-20 Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. Expired - Lifetime ES2190075T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/851,006 US5874418A (en) 1997-05-05 1997-05-05 Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use

Publications (1)

Publication Number Publication Date
ES2190075T3 true ES2190075T3 (es) 2003-07-16

Family

ID=25309709

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98918648T Expired - Lifetime ES2190075T3 (es) 1997-05-05 1998-04-20 Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.

Country Status (10)

Country Link
US (1) US5874418A (es)
EP (1) EP0980262B1 (es)
JP (1) JP3745382B2 (es)
KR (1) KR100378031B1 (es)
AT (1) ATE234634T1 (es)
AU (1) AU729671B2 (es)
CA (1) CA2289202C (es)
DE (1) DE69812343T2 (es)
ES (1) ES2190075T3 (es)
WO (1) WO1998050077A1 (es)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AU775037B2 (en) * 1998-12-09 2004-07-15 Eli Lilly And Company Pellet implant system
BR9812553B1 (pt) * 1997-09-25 2010-06-01 formulação medicamentosa em pélete de difusão controlada e em um sistema matriz.
US6500456B1 (en) * 1997-10-03 2002-12-31 Warner-Lambert Company Compressed nitroglycerin tablet and its method of manufacture
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
DE19941769A1 (de) * 1999-09-02 2001-03-08 Beiersdorf Ag Wirkstoffkombinationen bzw. Addukte aus Biotin und/oder Biotinderivaten und Cyclodextrinen und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen
AU783656B2 (en) * 1999-09-02 2005-11-24 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
US6346231B1 (en) * 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
US6294013B1 (en) * 1999-12-08 2001-09-25 Sun Chemical Corporation Polysaccharide pigment dispersions
US20030148996A1 (en) * 2000-03-31 2003-08-07 Joseph Rubinfeld Camptothecin complexes
PT1276470E (pt) * 2000-04-20 2007-08-13 Novartis Ag Composição de revestimento para dissimular o sabor
DE60136926D1 (de) * 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US6953586B1 (en) 2000-06-08 2005-10-11 Ivy Animal Health, Inc. Growth promoting pharmaceutical implant
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
IN190699B (es) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
DE10114364A1 (de) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Verfahren zur Herstellung von antibiotischen Kompositen
DE10114245A1 (de) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Herstellung und Verwendung einer Antibiotikum-/Antibiotika-Zubereitung
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
JP2005521690A (ja) * 2002-02-22 2005-07-21 ファルマシア・コーポレーション ゴム系を含む眼科用製剤
EP1478404A1 (en) * 2002-02-22 2004-11-24 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004087121A2 (en) * 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2005065435A2 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
ATE494298T1 (de) 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
BRPI0510119A (pt) * 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
AU2015255259B2 (en) * 2004-04-23 2017-07-27 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
SI2030981T1 (sl) * 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
EP2261236B1 (en) * 2004-12-07 2015-07-15 Onyx Therapeutics, Inc. Composition for proteasome inhibition
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
CA2592605C (en) * 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060183725A1 (en) * 2005-02-15 2006-08-17 Thomas Graeser Pharmaceutical preparation for oral contraception
RU2417103C2 (ru) * 2005-10-26 2011-04-27 Сайдекс Фармасьютикалз, Инк. Композиции простого сульфоалкилового эфира циклодекстрина и способы их получения
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
AU2011204957B2 (en) * 2005-10-26 2013-12-05 Cydex Pharmaceuticals, Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
EP1971346A2 (en) * 2005-12-20 2008-09-24 Tika Läkemedel AB Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
US20080069889A1 (en) * 2006-03-07 2008-03-20 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
US8639782B2 (en) 2006-08-23 2014-01-28 Ebay, Inc. Method and system for sharing metadata between interfaces
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
PL2061458T3 (pl) * 2006-09-15 2015-07-31 Univ Minnesota Kompozycje topiramatu i sposoby ich stosowania
ES2963291T3 (es) * 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2008148080A2 (en) * 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
BR122020021551B1 (pt) 2008-11-15 2021-09-21 Melinta Subsidiary Corp Composição farmacêutica antimicrobiana e seu uso
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
PL3100728T3 (pl) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
KR101522918B1 (ko) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US20110082098A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
EP2538923A2 (en) 2010-02-22 2013-01-02 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2012061409A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3166642B1 (en) 2014-06-18 2020-06-03 Audevard Transdermal formulations of pergolide and uses thereof
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PT3253208T (pt) 2015-02-02 2021-06-17 The Spanish National Cancer Res Centre Terapêuticas de combinação para utilização no tratamento do cancro da mama
US10702568B2 (en) 2015-03-19 2020-07-07 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
MX2019013053A (es) 2017-05-03 2020-02-07 Cydex Pharmaceuticals Inc Composicion que contiene ciclodextrina y busulfan.
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN115038723A (zh) 2019-11-18 2022-09-09 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
US20230227506A1 (en) 2020-06-18 2023-07-20 The University Of Bristol Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
US20230364106A1 (en) * 2020-09-21 2023-11-16 Sun Pharmaceutical Industries Limited Parenteral dosage form of diltiazem
US12698348B2 (en) 2020-09-24 2026-08-04 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN114128914B (zh) * 2021-12-02 2023-02-10 云南中烟工业有限责任公司 一种包合物、其制备方法及用途
JP2026517851A (ja) 2023-05-05 2026-06-02 ユーロ－セルティーク エス．エイ． がんを処置するための組合せ
WO2026085322A1 (en) 2024-10-18 2026-04-23 Aardvark Therapeutics Inc. Isoflavonoid formulations and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (es) * 1970-06-10 1975-02-04
NZ199543A (en) * 1981-01-23 1985-04-30 Wellcome Found Inclusion complexes of cyclodextrins and cardiac clycosides;pharmaceutical formulations
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0147685B1 (de) * 1983-12-17 1989-04-26 Hoechst Aktiengesellschaft Ether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
WO1998050077A1 (en) 1998-11-12
KR100378031B1 (ko) 2003-04-16
JP2002503267A (ja) 2002-01-29
ATE234634T1 (de) 2003-04-15
JP3745382B2 (ja) 2006-02-15
US5874418A (en) 1999-02-23
EP0980262B1 (en) 2003-03-19
CA2289202A1 (en) 1998-11-12
KR20010012233A (ko) 2001-02-15
AU7153598A (en) 1998-11-27
EP0980262A1 (en) 2000-02-23
AU729671B2 (en) 2001-02-08
DE69812343D1 (de) 2003-04-24
CA2289202C (en) 2005-03-15
DE69812343T2 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
BR9810495A (pt) Composição farmacêutica
NO952151L (no) Injiserbare, taxanderivat-baserte preparater
LU90283I2 (fr) Sporanox soluté buvable et ses dérivés pharmaceutiquement acceptables
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
ATE429210T1 (de) Orale flüssige zusammensetzungen
NZ512692A (en) Sulphoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
ATE212351T1 (de) Androsten-derivate
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
PL346764A1 (en) New oral formulation for 5-ht4
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
EA200100674A1 (ru) Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE397447T1 (de) Feste paroxetin enthaltende zubereitungen
MD1473G2 (ro) Remediu antiherpetic
DE60011620D1 (de) Tixocortolpivalathaltige pharmazeutische suspension,daraus hergestelltes mundwasser und diese suspension enthaltende verpackung
BG105178A (bg) Нови 2,3,3а,4,9,9а-хексахидро-8-хидрокси-1н-бенз/f/индоли, метод за получаването им и приложението им като лекарствени средства
DK1202992T3 (da) Ascididemin-derivater og terapeutiske anvendelser deraf
MY152490A (en) New oral formulation
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol
UA30393A (uk) Спосіб лікування коронарного атеросклерозу